Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for TARS
| Stock Name | Tarsus Pharmaceuticals Inc |
| Ticker | TARS(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US87650L1035 |
Show aggregate TARS holdings
News associated with TARS
- Blair William & Co. IL Trims Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
- Blair William & Co. IL decreased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 58.1% during the first quarter, Holdings Channel reports. The fund owned 11,416 shares of the company’s stock after selling 15,814 shares during the period. Blair William & Co. IL’s holdings in Tarsus Pharmaceuticals were worth $586,000 […] - 2025-08-11 05:52:54
- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of “Buy” from Brokerages
- Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) have earned a consensus rating of “Buy” from the seven analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-08-06 03:06:50
- Arizona State Retirement System Buys 470 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
- Arizona State Retirement System lifted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 6.1% during the first quarter, Holdings Channel.com reports. The firm owned 8,182 shares of the company’s stock after acquiring an additional 470 shares during the period. Arizona State Retirement System’s holdings in Tarsus Pharmaceuticals were worth $420,000 […] - 2025-07-23 05:44:46
- Brokerages Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) PT at $66.67
- Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) have been assigned a consensus recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to […] - 2025-06-20 02:36:52
- GAMMA Investing LLC Purchases 13,115 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
- GAMMA Investing LLC grew its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 36,430.6% in the first quarter, Holdings Channel reports. The fund owned 13,151 shares of the company’s stock after acquiring an additional 13,115 shares during the quarter. GAMMA Investing LLC’s holdings in Tarsus Pharmaceuticals were worth $676,000 at the end of […] - 2025-06-19 04:06:59
- UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
- UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 18.7% during the fourth quarter, HoldingsChannel reports. The fund owned 69,826 shares of the company’s stock after acquiring an additional 10,991 shares during the quarter. UBS AM a distinct […] - 2025-06-05 06:14:53
- Nuveen Asset Management LLC Has $6.95 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
- Nuveen Asset Management LLC trimmed its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 10.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 125,539 shares of the company’s stock after selling 15,186 shares during the quarter. Nuveen Asset […] - 2025-05-30 05:04:50
- Tarsus Pharmaceuticals (NASDAQ:TARS) Raised to Buy at HC Wainwright
- Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) was upgraded by equities research analysts at HC Wainwright to a “buy” rating in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm currently has a $72.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 71.22% from the […] - 2025-05-29 02:15:10
- Two Sigma Advisers LP Has $2.96 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
- Two Sigma Advisers LP reduced its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 79.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,500 shares of the company’s stock after selling 202,900 shares during the quarter. Two Sigma […] - 2025-05-28 07:09:12
- Two Sigma Investments LP Has $5.05 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
- Two Sigma Investments LP lowered its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 69.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 91,171 shares of the company’s stock after selling 204,832 shares during the quarter. […] - 2025-05-28 05:04:57
- Tarsus Pharmaceuticals (NASDAQ:TARS) and Dyadic International (NASDAQ:DYAI) Critical Survey
- Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) and Dyadic International (NASDAQ:DYAI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends. Earnings and Valuation This table compares Tarsus […] - 2025-05-27 02:17:08
- Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Target Price at $66.33
- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has earned an average recommendation of “Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation […] - 2025-05-26 03:08:58
- Dimensional Fund Advisors LP Cuts Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
- Dimensional Fund Advisors LP reduced its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 15.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 341,305 shares of the company’s stock after selling 62,658 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Tarsus Pharmaceuticals were worth $18,897,000 at […] - 2025-05-08 05:25:05
- The Goldman Sachs Group Forecasts Strong Price Appreciation for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock
- Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) had its target price upped by investment analysts at The Goldman Sachs Group from $46.00 to $51.00 in a report released on Monday,Benzinga reports. The firm currently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price would suggest a potential upside of 9.80% from […] - 2025-05-07 02:22:52
- Barclays PLC Sells 23,999 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
- Barclays PLC trimmed its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 24.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,664 shares of the company’s stock after selling 23,999 shares during the period. […] - 2025-04-28 05:01:20
- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Legal & General Group Plc
- Legal & General Group Plc trimmed its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 2.1% during the fourth quarter, Holdings Channel reports. The fund owned 26,595 shares of the company’s stock after selling 560 shares during the quarter. Legal & General Group Plc’s holdings in Tarsus Pharmaceuticals were worth $1,473,000 […] - 2025-04-27 05:42:58
- Wells Fargo & Company MN Has $3.16 Million Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
- Wells Fargo & Company MN raised its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 44.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 57,004 shares of the company’s stock after buying an additional 17,451 shares during the period. […] - 2025-04-24 04:32:51
- Geode Capital Management LLC Buys 3,014 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
- Geode Capital Management LLC lifted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 0.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 838,804 shares of the company’s stock after buying an additional 3,014 shares during the quarter. Geode […] - 2025-04-15 05:00:56
- Pictet Asset Management Holding SA Invests $284,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
- Pictet Asset Management Holding SA bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 5,130 shares of the company’s stock, valued at approximately $284,000. A number of other institutional investors and hedge funds have also recently bought and sold shares of the […] - 2025-04-11 06:24:52
- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Vanguard Group Inc.
- Vanguard Group Inc. boosted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 0.9% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 2,115,162 shares of the company’s stock after buying an additional 17,839 shares during the period. Vanguard Group Inc. owned 0.06% of Tarsus Pharmaceuticals worth $117,117,000 as […] - 2025-04-09 04:42:52
- Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up After Strong Earnings
- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $45.54, but opened at $47.44. Tarsus Pharmaceuticals shares last traded at $44.83, with a volume of 251,757 shares. The company reported ($0.60) earnings per share […] - 2025-02-27 05:10:47
- Allspring Global Investments Holdings LLC Has $10.03 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
- Allspring Global Investments Holdings LLC cut its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 14.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 181,122 shares of the company’s stock after selling 29,409 shares during the period. Allspring […] - 2025-02-19 07:08:18
- Bleakley Financial Group LLC Makes New $323,000 Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
- Bleakley Financial Group LLC bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) in the fourth quarter, Holdings Channel reports. The firm bought 5,825 shares of the company’s stock, valued at approximately $323,000. A number of other large investors have also recently added to or reduced their stakes in the […] - 2025-02-12 06:57:10
- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of “Buy” from Brokerages
- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been assigned an average recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the […] - 2025-02-12 04:40:57
- Tarsus Pharmaceuticals (NASDAQ:TARS) Given Buy Rating at Guggenheim
- Guggenheim reissued their buy rating on shares of Tarsus Pharmaceuticals (NASDAQ:TARS – Free Report) in a research report released on Monday morning,Benzinga reports. A number of other equities analysts have also weighed in on the stock. Barclays boosted their price objective on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an […] - 2025-02-11 05:09:04
iShares MSCI World Small Cap UCITS ETF USD (Acc) TARS holdings
| Date | Number of TARS Shares Held | Base Market Value of TARS Shares | Local Market Value of TARS Shares | Change in TARS Shares Held | Change in TARS Base Value | Current Price per TARS Share Held | Previous Price per TARS Share Held |
|---|
| 2025-11-27 (Thursday) | 24,285 | USD 1,954,943 | USD 1,954,943 | 0 | USD 0 | USD 80.5 | USD 80.5 |
| 2025-11-26 (Wednesday) | 24,285 | USD 1,954,943 | USD 1,954,943 | -46 | USD 35,714 | USD 80.5 | USD 78.88 |
| 2025-11-25 (Tuesday) | 24,331 | USD 1,919,229 | USD 1,919,229 | 0 | USD -78,589 | USD 78.88 | USD 82.11 |
| 2025-11-24 (Monday) | 24,331 | USD 1,997,818 | USD 1,997,818 | 0 | USD 59,611 | USD 82.11 | USD 79.66 |
| 2025-11-21 (Friday) | 24,331 | USD 1,938,207 | USD 1,938,207 | 0 | USD 65,207 | USD 79.66 | USD 76.98 |
| 2025-11-20 (Thursday) | 24,331 | USD 1,873,000 | USD 1,873,000 | 144 | USD 7,940 | USD 76.98 | USD 77.11 |
| 2025-11-19 (Wednesday) | 24,187 | USD 1,865,060 | USD 1,865,060 | 1,440 | USD 114,223 | USD 77.11 | USD 76.97 |
| 2025-11-18 (Tuesday) | 22,747 | USD 1,750,837 | USD 1,750,837 | 0 | USD 63,692 | USD 76.97 | USD 74.17 |
| 2025-11-17 (Monday) | 22,747 | USD 1,687,145 | USD 1,687,145 | 0 | USD 28,434 | USD 74.17 | USD 72.92 |
| 2025-11-14 (Friday) | 22,747 | USD 1,658,711 | USD 1,658,711 | -184 | USD -4,474 | USD 72.92 | USD 72.53 |
| 2025-11-13 (Thursday) | 22,931 | USD 1,663,185 | USD 1,663,185 | 0 | USD -52,283 | USD 72.53 | USD 74.81 |
| 2025-11-12 (Wednesday) | 22,931 | USD 1,715,468 | USD 1,715,468 | 0 | USD -19,033 | USD 74.81 | USD 75.64 |
| 2025-11-11 (Tuesday) | 22,931 | USD 1,734,501 | USD 1,734,501 | 0 | USD 65,354 | USD 75.64 | USD 72.79 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of TARS by Blackrock for IE00BF4RFH31
Show aggregate share trades of TARS| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-11-26 | SELL | -46 | | | 80.500* | | 49.87 Profit of 2,294 on sale |
| 2025-11-20 | BUY | 144 | | | 76.980* | | 49.34 |
| 2025-11-19 | BUY | 1,440 | | | 77.110* | | 49.21 |
| 2025-11-14 | SELL | -184 | | | 72.920* | | 48.86 Profit of 8,990 on sale |
| 2025-10-29 | BUY | 92 | 67.520 | 69.325 | 69.144 | USD 6,361 | 47.59 |
| 2025-10-21 | BUY | 184 | 70.820 | 71.485 | 71.419 | USD 13,141 | 46.96 |
| 2025-10-07 | BUY | 92 | 68.420 | 69.490 | 69.383 | USD 6,383 | 46.60 |
| 2025-09-08 | SELL | -184 | 56.890 | 57.510 | 57.448 | USD -10,570 | 45.98 Loss of -2,110 on sale |
| 2025-08-15 | BUY | 92 | 54.210 | 55.070 | 54.984 | USD 5,059 | 45.93 |
| 2025-08-07 | BUY | 276 | 47.950 | 48.210 | 48.184 | USD 13,299 | 45.89 |
| 2025-07-29 | BUY | 92 | 40.140 | 42.130 | 41.931 | USD 3,858 | 46.06 |
| 2025-07-14 | BUY | 188 | 41.530 | 41.700 | 41.683 | USD 7,836 | 46.24 |
| 2025-06-30 | BUY | 188 | 40.510 | 41.500 | 41.401 | USD 7,783 | 46.49 |
| 2025-06-25 | BUY | 282 | 40.200 | 42.000 | 41.820 | USD 11,793 | 46.60 |
| 2025-06-20 | SELL | -47 | 40.650 | 41.300 | 41.235 | USD -1,938 | 46.71 Profit of 257 on sale |
| 2025-06-12 | SELL | -376 | 40.950 | 41.470 | 41.418 | USD -15,573 | 46.95 Profit of 2,078 on sale |
| 2025-06-02 | BUY | 141 | 43.850 | 44.320 | 44.273 | USD 6,242 | 47.17 |
| 2025-05-28 | BUY | 94 | 42.050 | 42.835 | 42.756 | USD 4,019 | 47.26 |
| 2025-05-14 | BUY | 47 | 42.900 | 43.123 | 43.101 | USD 2,026 | 47.55 |
| 2025-05-13 | BUY | 94 | 41.460 | 44.160 | 43.890 | USD 4,126 | 47.60 |
| 2025-05-07 | BUY | 141 | 47.350 | 48.315 | 48.218 | USD 6,799 | 47.66 |
| 2025-04-28 | BUY | 46 | 49.720 | 50.500 | 50.422 | USD 2,319 | 47.56 |
| 2025-04-16 | BUY | 611 | 49.390 | 49.460 | 49.453 | USD 30,216 | 47.43 |
| 2025-04-14 | BUY | 94 | 48.720 | 48.725 | 48.724 | USD 4,580 | 47.40 |
| 2025-04-08 | SELL | -94 | 44.630 | 49.005 | 48.568 | USD -4,565 | 47.48 Loss of -102 on sale |
| 2025-04-04 | SELL | -94 | 47.020 | 48.800 | 48.622 | USD -4,570 | 47.48 Loss of -107 on sale |
| 2025-03-28 | BUY | 470 | 51.740 | 52.300 | 52.244 | USD 24,555 | 47.35 |
| 2025-03-12 | SELL | -94 | 47.100 | 49.900 | 49.620 | USD -4,664 | 47.09 Loss of -237 on sale |
| 2025-03-04 | SELL | -94 | 44.500 | 45.680 | 45.562 | USD -4,283 | 47.19 Profit of 153 on sale |
| 2025-02-26 | SELL | -188 | 42.560 | 43.760 | 43.640 | USD -8,204 | 47.39 Profit of 706 on sale |
| 2025-02-13 | BUY | 47 | 52.230 | 53.220 | 53.121 | USD 2,497 | 47.25 |
| 2025-02-12 | BUY | 188 | 52.330 | 52.970 | 52.906 | USD 9,946 | 47.17 |
| 2025-01-27 | BUY | 47 | 51.450 | 54.080 | 53.817 | USD 2,529 | 45.93 |
| 2025-01-23 | BUY | 47 | 49.120 | 50.015 | 49.925 | USD 2,346 | 45.82 |
| 2024-12-09 | BUY | 1,692 | 50.660 | 51.890 | 51.767 | USD 87,590 | 45.53 |
| 2024-12-04 | BUY | 94 | 51.640 | 52.130 | 52.081 | USD 4,896 | 45.17 |
| 2024-12-03 | BUY | 141 | 50.400 | 51.020 | 50.958 | USD 7,185 | 45.05 |
| 2024-11-19 | BUY | 288 | 46.890 | 46.900 | 46.899 | USD 13,507 | 43.64 |
| 2024-11-18 | BUY | 96 | 44.630 | 46.790 | 46.574 | USD 4,471 | 43.61 |
| 2024-11-12 | BUY | 188 | 47.570 | 49.623 | 49.418 | USD 9,291 | 43.49 |
| 2024-11-11 | BUY | 47 | 49.080 | 50.920 | 50.736 | USD 2,385 | 43.11 |
| 2024-11-11 | BUY | 47 | 49.080 | 50.920 | 50.736 | USD 2,385 | 43.11 |
| 2024-11-07 | BUY | 235 | 46.790 | 47.400 | 47.339 | USD 11,125 | 42.34 |
| 2024-11-07 | BUY | 235 | 46.790 | 47.400 | 47.339 | USD 11,125 | 42.34 |
| 2024-10-23 | BUY | 94 | 39.000 | 39.160 | 39.144 | USD 3,680 | 37.23 |
| 2024-10-23 | BUY | 94 | 39.000 | 39.160 | 39.144 | USD 3,680 | 37.23 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of TARS
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 252,801 | 0 | 426,166 | 59.3% |
| 2025-09-18 | 137,976 | 0 | 230,324 | 59.9% |
| 2025-09-17 | 350,436 | 5 | 543,379 | 64.5% |
| 2025-09-16 | 169,762 | 23 | 341,917 | 49.7% |
| 2025-09-15 | 188,220 | 0 | 351,011 | 53.6% |
| 2025-09-12 | 173,824 | 19 | 536,802 | 32.4% |
| 2025-09-11 | 254,169 | 0 | 587,029 | 43.3% |
| 2025-09-10 | 130,049 | 21,726 | 202,273 | 64.3% |
| 2025-09-09 | 81,081 | 0 | 152,616 | 53.1% |
| 2025-09-08 | 127,262 | 13,834 | 268,329 | 47.4% |
| 2025-09-05 | 111,598 | 0 | 279,260 | 40.0% |
| 2025-09-04 | 157,740 | 6,413 | 224,745 | 70.2% |
| 2025-09-03 | 72,242 | 1,200 | 191,629 | 37.7% |
| 2025-09-02 | 219,449 | 0 | 325,874 | 67.3% |
| 2025-08-29 | 62,133 | 0 | 140,050 | 44.4% |
| 2025-08-28 | 50,541 | 0 | 159,808 | 31.6% |
| 2025-08-27 | 36,919 | 0 | 92,543 | 39.9% |
| 2025-08-26 | 63,628 | 0 | 154,058 | 41.3% |
| 2025-08-25 | 72,109 | 0 | 148,872 | 48.4% |
| 2025-08-22 | 80,786 | 0 | 201,829 | 40.0% |
| 2025-08-21 | 73,646 | 0 | 231,979 | 31.7% |
| 2025-08-20 | 93,401 | 891 | 221,733 | 42.1% |
| 2025-08-19 | 42,418 | 0 | 137,197 | 30.9% |
| 2025-08-18 | 116,541 | 20,164 | 304,699 | 38.2% |
| 2025-08-15 | 133,688 | 400 | 335,133 | 39.9% |
| 2025-08-14 | 81,791 | 328 | 173,473 | 47.1% |
| 2025-08-13 | 119,902 | 0 | 340,392 | 35.2% |
| 2025-08-12 | 113,528 | 0 | 262,067 | 43.3% |
| 2025-08-11 | 247,112 | 200 | 586,919 | 42.1% |
| 2025-08-08 | 164,594 | 0 | 266,105 | 61.9% |
| 2025-08-07 | 425,029 | 300 | 765,615 | 55.5% |
| 2025-08-06 | 173,644 | 39 | 252,868 | 68.7% |
| 2025-08-05 | 89,019 | 5 | 111,443 | 79.9% |
| 2025-08-04 | 104,357 | 20 | 207,097 | 50.4% |
| 2025-08-01 | 273,972 | 0 | 370,178 | 74.0% |
| 2025-07-31 | 170,413 | 0 | 271,101 | 62.9% |
| 2025-07-30 | 92,228 | 0 | 317,929 | 29.0% |
| 2025-07-29 | 142,684 | 0 | 285,141 | 50.0% |
| 2025-07-28 | 123,438 | 31 | 191,764 | 64.4% |
| 2025-07-25 | 123,025 | 336 | 162,520 | 75.7% |
| 2025-07-24 | 122,485 | 10 | 171,350 | 71.5% |
| 2025-07-23 | 115,791 | 0 | 149,653 | 77.4% |
| 2025-07-22 | 84,089 | 10 | 133,731 | 62.9% |
| 2025-07-21 | 196,108 | 151 | 244,905 | 80.1% |
| 2025-07-18 | 290,801 | 482 | 509,804 | 57.0% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.